| antioxidant effect |
001 |
| fibrosis |
001 |
| oxidative stress |
001 |
| scleroderma |
001 |
| ankylosing spondylitis |
018, 009, 044 |
| balance |
018 |
| lumbopelvic mismatch |
018 |
| sagittal spinopelvic alignment |
018 |
| autoimmune disease |
009 |
| interferons |
009 |
| treatment |
009 |
| child |
096 |
| complement 2 |
096 |
| cutaneous vasculitis |
096 |
| systemic lupus erythematosus |
096, 108, 034 |
| career planning |
026 |
| compulsory service |
026 |
| physical and rehabilitation medicine resident |
026 |
| subspecialty training |
026 |
| posture |
044 |
| spine |
044 |
| flow cytometry |
053 |
| myeloid-derived suppressor cells |
053 |
| rheumatoid arthritis |
053, 071, 079 |
| sjögren’s syndrome |
053 |
| fetuin-a |
071 |
| insulin resistance |
071 |
| interleukin-6 |
071 |
| serum tumor necrosis factor-like weak inducer of apoptosis |
071 |
| adam12 |
062 |
| osteoarthritis |
062 |
| polymorphism |
062 |
| body image disturbance |
079 |
| chinese patients |
079 |
| hypertension |
088 |
| lupus erythematosus |
088 |
| pulmonary |
088 |
| risk factors |
088 |
| systemic |
088 |
| anti-tumor necrosis factor treatment |
100 |
| paradoxical side effect |
100 |
| psoriasis |
100 |
| aortic pseudocoarctation |
105 |
| computed tomography |
105 |
| mitral valve perforation |
105 |
| takayasu’s arteritis |
105 |
| two- and three-dimensional transesophageal echocardiography |
105 |
| aseptic |
108 |
| central nervous system |
108 |
| meningitis |
108 |
| neuropsychiatric |
108 |
| immune-related adverse events |
112 |
| nivolumab |
112 |
| seronegative arthritis |
112 |
| antimalarials |
034 |
| cutaneous lupus erythematosus |
034 |
| dermatomyositis |
034 |
| mepacrine |
034 |
| quinacrine |
034 |
